Zealand Pharma Forecast, price target & analysts
Zealand Pharma Target price 2025 - Analyst rating & recommendation
Zealand Pharma Classifications & Recommendation:
Zealand Pharma Price Target
| Target Price | DKK962.25 |
| Price | DKK663.00 |
| Potential |
45.14%
register free of charge
|
| Number of Estimates | 12 |
|
12 Analysts have issued a price target Zealand Pharma 2026 .
The average Zealand Pharma target price is DKK962.25.
This is
45.14%
register free of charge
DKK1,100.00
65.91%
register free of charge
DKK750.00
13.12%
register free of charge
|
|
| A rating was issued by 13 analysts: 11 Analysts recommend Zealand Pharma to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Zealand Pharma stock has an average upside potential 2026 of
45.14%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million DKK | 62.69 | 856.68 |
| 81.71% | 1,266.54% | |
| EBITDA Margin | -1,983.12% | -69.22% |
| 1,175.58% | 96.51% | |
| Net Margin | -1,830.21% | -43.00% |
| 613.83% | 97.65% |
11 Analysts have issued a sales forecast Zealand Pharma 2025 . The average Zealand Pharma sales estimate is
This results in the following potential growth metrics:
10 Analysts have issued an Zealand Pharma EBITDA forecast 2025. The average Zealand Pharma EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
7 Zealand Pharma Analysts have issued a net profit forecast 2025. The average Zealand Pharma net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share DKK | -16.24 | -5.21 |
| 30.55% | 67.92% | |
| P/E | negative | |
| EV/Sales | 48.17 |
7 Analysts have issued a Zealand Pharma forecast for earnings per share. The average Zealand Pharma <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Based on analysts' sales estimates for 2025, the Zealand Pharma stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of
This results in the following potential growth metrics and future valuations:
Current Zealand Pharma Upgrades & Downgrades Beta
| Analyst | Rating | Action | Date |
|---|---|---|---|
| KBC SECURITIES | Locked ➜ Locked | Locked | Dec 22 2024 |
| BTIG | Locked ➜ Locked | Locked | Dec 21 2024 |
| CANTOR FITZGERALD | Locked ➜ Locked | Locked | Dec 19 2024 |
| DNB MARKETS | Locked ➜ Locked | Locked | Dec 19 2024 |
| BERENBERG | Locked ➜ Locked | Locked | Dec 10 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
KBC SECURITIES: Locked ➜ Locked
|
Dec 22 2024 |
|
Locked
BTIG: Locked ➜ Locked
|
Dec 21 2024 |
|
Locked
CANTOR FITZGERALD: Locked ➜ Locked
|
Dec 19 2024 |
|
Locked
DNB MARKETS: Locked ➜ Locked
|
Dec 19 2024 |
|
Locked
BERENBERG: Locked ➜ Locked
|
Dec 10 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
